m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG03596)
Name
ISIS 113019
Status
Investigative
TTD Drug ID
D0E4IZ
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
E2F transcription factor 1 (E2F1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113019. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of ISIS 113019 through regulating the expression of E2F transcription factor 1 (E2F1). [1], [2]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113019. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ISIS 113019 through regulating the expression of E2F transcription factor 1 (E2F1). [2], [3]
YTH domain-containing family protein 1 (YTHDF1)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary E2F transcription factor 1 (E2F1) is a therapeutic target for ISIS 113019. The YTH domain-containing family protein 1 (YTHDF1) has potential in affecting the response of ISIS 113019 through regulating the expression of E2F transcription factor 1 (E2F1). [1], [2]
References
Ref 1 Correlation of m6A methylation with immune infiltrates and poor prognosis in non-small cell lung cancer via a comprehensive analysis of RNA expression profiles. Ann Transl Med. 2021 Sep;9(18):1465. doi: 10.21037/atm-21-4248.
Ref 2 US patent application no. 6,187,587, Antisense inhibition of e2f transcription factor 1 expression.
Ref 3 Effect of m6A methyltransferase METTL3 -mediated MALAT1/E2F1/AGR2 axis on adriamycin resistance in breast cancer. J Biochem Mol Toxicol. 2022 Jan;36(1):e22922. doi: 10.1002/jbt.22922. Epub 2021 Dec 28.